Olanzapine Activates Hepatic Mammalian Target of Rapamycin: New Mechanistic Insight into Metabolic Dysregulation with Atypical Antipsychotic Drugs

Olanzapine (OLZ), an effective treatment of schizophrenia and other disorders, causes weight gain and metabolic syndrome. Most studies to date have focused on the potential effects of OLZ on the central nervous system’s mediation of weight; however, peripheral changes in liver or other key metabolic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schmidt, Robin H., Jokinen, Jenny D., Massey, Veronica L., Falkner, K. Cameron, Shi, Xue, Yin, Xinmin, Zhang, Xiang, Beier, Juliane I., Arteel, Gavin E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: The American Society for Pharmacology and Experimental Therapeutics 2013
Schlagworte:
Gastrointestinal, Hepatic, Pulmonary, and Renal
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3781405/
https://ncbi.nlm.nih.gov/pubmed/23926289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.113.207621
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge